Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 30;10(13):2959. doi: 10.3390/jcm10132959

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Oncological survival in intrahepatic cholangiocarcinoma stratified by radiologic features. (A) Overall survival (OS) stratified by number of nodules. The median OS was 32 months in patients with a single nodule, 21 months in patients with 2–3 nodules, 22 months in patients with 4–5, and 10 months in patients with >5 nodules. (B) Recurrence-free survival (RFS) stratified by number of nodules. The median RFS was 26 months in patients with a single nodule, 8 months in patients with 2–3 nodules, 10 months in patients with 4–5, and 4 months in patients with >5 nodules. (C) Overall survival stratified by largest tumor diameter. The mean OS was 142 months in patients with a largest tumor diameter ≤3 cm, while the median OS was 22 months in patients with >3 cm and ≤5 cm, 25 months in patients with >5 cm and ≤10 cm, 12 months in patients with >10 cm and ≤15 cm, and 19 months patients with >15 cm. (D) Recurrence-free survival stratified by largest tumor diameter. The mean RFS was 144 months in patients with a largest tumor diameter ≤3 cm, while the median RFS was 18 months in patients with >3 cm and ≤5 cm, 12 months in patients with >5 cm and ≤10 cm, 7 months in patients with >10 cm and ≤15 cm, and 5 months patients with >15 cm. (E) Overall survival stratified by macrovascular invasion. The median OS was 32 months in patients without macrovascular invasion and 16 months in patients with macrovascular invasion. (F) Recurrence-free survival stratified by macrovascular invasion. The median RFS was 20 months in patients without macrovascular invasion and 7 months in patients with macrovascular invasion. (G) Overall survival with respect to risk stratification. The mean OS was 142 months in patients with a single nodule ≤3 cm, while the median OS was 28 months in patients with a single nodule >3 cm and 19 months in patients with ≥2 nodules. (H) Recurrence-free survival with respect to risk stratification. The mean RFS was 144 months in patients with a single nodule ≤3 cm, while the median RFS was 17 months in patients with a single nodule >3 cm, and 7 months in patients with ≥2 nodules.